XTL Biopharmaceuticals Ltd. (XTLB)

XTL Biopharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	0.37	1.4	2.09	2.97	3.63
Trading Asset Securities	0.77	0.61	1.63	3.16	2.41
Cash & Short-Term Investments	1.14	2.01	3.72	6.13	6.04
Cash Growth	-43.02%	-46.09%	-39.27%	1.41%	-10.20%
Accounts Receivable	0.1	-	-	-	-
Receivables	0.1	-	-	-	-
Prepaid Expenses	0.05	0.03	0.07	0.09	0.07
Other Current Assets	0.05	0.01	0.01	0.02	0.01
Total Current Assets	1.34	2.05	3.81	6.24	6.12
Property, Plant & Equipment	0.19	-	-	0	0
Goodwill	3.19	-	-	-	-
Other Intangible Assets	3.82	0.38	0.38	0.38	0.38
Other Long-Term Assets	0.01	-	-	-	-
Total Assets	8.55	2.43	4.19	6.62	6.5
Accounts Payable	0.23	0	0	0	0
Accrued Expenses	0.55	0.21	0.19	0.23	0.25
Short-Term Debt	0.14	-	-	-	-
Current Unearned Revenue	0.02	-	-	-	-
Other Current Liabilities	1.28	-	-	-	-
Total Current Liabilities	2.21	0.21	0.19	0.23	0.25
Long-Term Deferred Tax Liabilities	0.22	-	-	-	-
Other Long-Term Liabilities	0.69	-	-	1.05	2.64
Total Liabilities	3.12	0.21	0.19	1.29	2.89
Common Stock	23.14	14.12	14.12	14.12	13.18
Additional Paid-In Capital	141.29	146.33	146.33	146.33	146.02
Retained Earnings	-159.01	-158.25	-156.47	-155.13	-155.61
Comprehensive Income & Other	0.02	0.02	0.02	0.02	0.02
Total Common Equity	5.44	2.22	4	5.33	3.61
Shareholders' Equity	5.44	2.22	4	5.33	3.61
Total Liabilities & Equity	8.55	2.43	4.19	6.62	6.5
Total Debt	0.14	-	-	-	-
Net Cash (Debt)	1.01	2.01	3.72	6.13	6.04
Net Cash Growth	-49.90%	-46.09%	-39.27%	1.41%	-10.20%
Net Cash Per Share	0.00	0.00	0.01	0.01	0.01
Filing Date Shares Outstanding	881.39	544.91	544.91	544.91	514.21
Total Common Shares Outstanding	881.39	544.91	544.91	544.91	514.21
Working Capital	-0.87	1.84	3.62	6.01	5.87
Book Value Per Share	0.01	0.00	0.01	0.01	0.01
Tangible Book Value	-1.57	1.84	3.62	4.95	3.23
Tangible Book Value Per Share	-0.00	0.00	0.01	0.01	0.01

Updated Dec 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q